Cartalax (50mg)

What is Cartalax (50mg)?

Cartalax (50mg) is an ultrashort tripeptide commonly identified in research as AED (Ala–Glu–Asp). In scientific and catalog descriptions, it is typically placed within the bioregulator or organ-specific bioregulator peptide groupings and is most often discussed in experimental contexts related to cartilage and connective tissue.

In these models, Cartalax is typically examined alongside markers of fibroblast function, extracellular matrix regulation, and tissue remodeling pathways under controlled in vitro or preclinical conditions.

In laboratory work, AED serves as a defined, low-complexity peptide that helps researchers run controlled studies without introducing large, multi-domain proteins. It may be included in in-vitro or preclinical models, where investigators track changes in cell signaling, gene-expression markers, and matrix-related endpoints, depending on the assay design.

These observations are model-dependent and should be interpreted strictly as non-clinical research findings. Because it is a short sequence, it is also useful for method development, stability checks, and comparative peptide screening workflows.

Product Specifications

• Category: Peptides
• Subcategory: Organ‑Specific & Bioregulator Peptides
• Peptide Name: Cartalax
• Chemical Formula: C₁₂H₁₉N₃O₈
• Molecular Weight: 333.29 g/mol
• Synonym: AEDR peptide
• Peptide Sequence: Ala–Glu–Asp (AED)
• Purity: ≥99% (HPLC‑verified; identity confirmed by standard analytical methods).
• Packaging Format: 50 mg lyophilized (freeze‑dried) powder in a sealed research‑use vial.
• Storage Conditions: Store at -20°C, avoid light exposure
• Intended Use: For laboratory research use only; not for human or veterinary use.

Key Characteristics of Cartalax (50mg)

• Defined ultrashort sequence (AED): A simple tripeptide format used as a controlled research material in peptide studies.
• Common research positioning: Frequently discussed within “bioregulator peptide” literature, including cartilage‑ and connective‑tissue–oriented experimental contexts.
• High-purity specification (≥99%): Intended to support reproducibility and reduce confounding from impurities in analytical workflows.
• Suitable for controlled experimental systems: Typically used where investigators want a small, well-defined peptide for assays involving cell behavior, extracellular matrix markers, or gene‑expression readouts in cartilage‑ or connective‑tissue–oriented models (study‑dependent).
• Research Use Only positioning: Not intended for diagnostic, therapeutic, or clinical applications.

How Cartalax (50mg) Supports Research

In laboratory research, Cartalax (AED) is most commonly used as a test article in studies that explore how short peptides may influence cell signaling pathways and downstream gene-expression markers in controlled models.

Published reviews and preclinical papers discuss AED peptides in relation to cell-function readouts (e.g., fibroblast or cartilage-adjacent experimental systems), but these findings are non-clinical and should be interpreted strictly within the limits of the study design.

Research Applications & Usage Information

Cartalax (50mg) is commonly referenced in research contexts such as:

• Tissue‑response and regeneration models: Used to evaluate changes in healing‑associated endpoints, extracellular matrix behavior, or repair signaling in cartilage‑ and connective‑tissue–oriented preclinical designs.
• Cell‑culture investigations: Evaluated in vitro in studies examining cell proliferation markers, apoptosis‑associated markers, and extracellular‑matrix remodeling indicators in controlled fibroblast culture conditions (study‑specific endpoints).
• Gene‑expression/regulation research: Included in broader research discussions of short peptides as potential modulators of gene‑expression signatures in experimental models.
• DNA/chromatin interaction assays: In vitro research exploring peptide binding to DNA and related biophysical readouts (e.g., melting temperature shifts).
• Method development/comparative peptide panels: Use as one component in short‑peptide screening panels, where multiple sequences are compared under the same assay conditions.

Handling and Storage Recommendations

• Store at -20°C and protect from light to help maintain peptide integrity.
• Keep the container tightly closed when not in use to limit moisture exposure.
• Avoid unnecessary temperature cycling (e.g., repeated warm–cool transitions), which can increase the risk of degradation for many synthetic peptides.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. Published 2021 Nov 22. doi:10.3390/molecules26227053
2. Lin’kova NS, Drobintseva AO, Orlova OA, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016;161(1):175-178. doi:10.1007/s10517-016-3370-x
3. Khavinson VK, Lin’kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292. doi:10.1007/s10517-016-3596-7
4. National Center for Biotechnology Information. PubChem Compound Summary for CID 87815447, Alanyl-glutamyl-aspartic acid. https://pubchem.ncbi.nlm.nih.gov/compound/Alanyl-glutamyl-aspartic-acid.